Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, five have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $229.50.

A number of equities analysts recently weighed in on QNCX shares. Citizens Jmp raised shares of Quince Therapeutics from a “market perform” rating to an “outperform” rating and set a $77.00 target price for the company in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $70.00 price target on shares of Quince Therapeutics in a report on Tuesday, August 18th. Oppenheimer began coverage on Quince Therapeutics in a report on Wednesday, July 29th. They set an “outperform” rating and a $82.00 price target for the company. Citigroup raised Quince Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Finally, Lifesci Capital upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Monday, June 29th.

Quince Therapeutics Stock Performance

NASDAQ:QNCX opened at $30.15 on Friday. The company has a market capitalization of $30.75 million, a PE ratio of -0.19 and a beta of 1.31. The company has a 50 day simple moving average of $28.18 and a two-hundred day simple moving average of $23.90. Quince Therapeutics has a fifty-two week low of $15.10 and a fifty-two week high of $909.98.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings results on Friday, August 14th. The company reported ($12.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($28.02) by $15.71.

Hedge Funds Weigh In On Quince Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Quince Therapeutics during the 2nd quarter worth approximately $31,000. Intellectus Partners LLC acquired a new position in shares of Quince Therapeutics during the 4th quarter valued at $179,000. Finally, 683 Capital Management LLC acquired a new position in shares of Quince Therapeutics during the 4th quarter valued at $798,000. 30.75% of the stock is owned by institutional investors and hedge funds.

About Quince Therapeutics

Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The company’s research centers on its erythrocyte-derived extracellular vesicle (EEV) platform, which uses patients’ red blood cells to encapsulate and deliver therapeutic compounds.

Quince’s lead investigational product is eDSP, formerly known as EryDex, an autologous red-blood-cell-based formulation of dexamethasone sodium phosphate being developed for ataxia-telangiectasia (A-T).